Group 1 - The 17th China Bioindustry Conference highlighted the theme "Biotechnology Empowering the Future, Biomanufacturing Reshaping the World," showcasing the latest achievements in China's biotechnology and biomanufacturing sectors [1] - Wuhan has developed a comprehensive biopharmaceutical industry cluster, with a scale exceeding 550 billion yuan, playing a significant role in both national and global biomanufacturing [1] - The "China Bioeconomy Development Report 2025" indicates that China ranks second globally in research centers and is a major player in the biopharmaceutical market, gradually participating in international competition [1][2] Group 2 - In 2024, China approved 93 new drugs, the highest in five years, and is now the second-largest biopharmaceutical market globally, with a growing number of research drugs [2] - China leads the world in medical device patent applications, with 91,513 applications, accounting for nearly 70% of the global total [2] - The Hubei Pathology Big Data Database is expected to exceed 5 million high-precision digital slices by the end of 2025, significantly enhancing medical institutions and driving innovation [2] Group 3 - China's bioeconomy is robust, with a steady growth trend, and the global bioeconomy is projected to grow from $40-50 trillion to $30 trillion by 2050, with a compound annual growth rate of 8.6% [3] - Advances in synthetic biology and high-throughput screening technologies have led to significant breakthroughs in the production of pharmaceutical chemicals using microbial cell factories [3] - In the field of agricultural biotechnology, China accounts for 23% of the global market share in biological breeding, which has effectively reduced production costs and pesticide usage [3]

2025.09. 05 本文字数：2295，阅读时长大约4分钟 作者 | 第一财经 周芳 CAR-T细胞疗法研究中心数量位居全球第二；生物药市场规模突破1.1万亿元，生物药在研数量蝉联全球第二；阶梯医疗在上海华山医院完成国内首例 脑机接口前瞻性临床试验；湖北病理大数据库179万张高精度数字切片跃居全球第二…… 其中，细胞和基因疗法稳定增长。2024年，全球共有2069个CAR-T临床研究中心，比2020年的1297个增加了60%，其中包括中国的388个研究中 心。中国拥有全球第二多的研究中心。精准生物儿童白血病CAR-T治疗产品"普基奥仑赛注射液"填补了国内空白，2025年有望成为国内首创、全球第 二款治疗该适应症的一类生物新药。 自研新药比例排名创新高。2024年，中国国家药品监督管理局共批准了93款新药，创近五年新高。中国已跻身全球第二大生物药市场，满足内需的同 时也将逐步进入国际市场。2024年，中国在研药物数量位居全球第2位，与美国的差距逐步缩小。2024年全球制药公司研发管线规模排名前25强中， 共有4家中国企业上榜，创造了新的历史纪录。以自研新药比例作为衡量标准，恒瑞医药排名全球第1位。 截至20 ...

其中，细胞和基因疗法稳定增长。2024年，全球共有2069个CAR-T临床研究中心，比2020年的1297个增 加了60%，其中包括中国的388个研究中心。中国拥有全球第二多的研究中心。精准生物儿童白血病 CAR-T治疗产品"普基奥仑赛注射液"填补了国内空白，2025年有望成为国内首创、全球第二款治疗该适 应症的一类生物新药。 自研新药比例排名创新高。2024年，中国国家药品监督管理局共批准了93款新药，创近五年新高。中国 已跻身全球第二大生物药市场，满足内需的同时也将逐步进入国际市场。2024年，中国在研药物数量位 居全球第2位，与美国的差距逐步缩小。2024年全球制药公司研发管线规模排名前25强中，共有4家中国 企业上榜，创造了新的历史纪录。以自研新药比例作为衡量标准，恒瑞医药排名全球第1位。 CAR-T细胞疗法研究中心数量位居全球第二；生物药市场规模突破1.1万亿元，生物药在研数量蝉联全 球第二；阶梯医疗在上海华山医院完成国内首例脑机接口前瞻性临床试验；湖北病理大数据库179万张 高精度数字切片跃居全球第二…… 9月4日，中国生物工程学会理事长高福在第十七届中国生物产业大会上发布《中国生物经济发展报告 ...

Group 1: Overview of China's Biomanufacturing Industry - The value added by the biomanufacturing sector accounts for over 7% of China's GDP [4] - China ranks second globally in the number of CAR-T cell therapy research centers and the number of biopharmaceuticals under research [1][4] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with a significant number of innovative drugs and research pipelines [5] Group 2: Innovations and Developments - The "National Innovation Drug Insight System" was launched to enhance the efficiency of innovative drug development and address industry challenges [7] - The Hubei Pathology Big Database has reached 170,000 high-precision digital slices, positioning it as the second largest globally [6] - The global CAR-T clinical research centers have increased by 60% from 2020 to 2024, with China contributing 388 centers [5] Group 3: Market Growth and Future Projections - The global biomanufacturing market is projected to grow significantly, with the biobased chemicals market expected to reach $125.23 billion by 2029 [8] - China's biomanufacturing sector is positioned as a new engine for economic growth, supported by national policies and strategic planning [8] - The biotechnological innovations in agriculture, such as genetically modified crops, are set to enter the industrialization demonstration phase in 2024 [9]